Literature DB >> 75939

In vivo effects of anti-Ia alloantisera. I. Elimination of specific suppression by in vivo administration of antisera specific for I-J controlled determinants.

M Pierres, R N Germain, M E Dorf, B Benacerraf.   

Abstract

The in vivo effects of intravenous administration of alloantisera directed to I-J subregion coded determinants were investigated. In confirmation and extension of our previous results, anti-I-Jk [B10.A(3R) anti-B10.A(5R)] and anti-I-Js ([B10.A(3R) X B10.S(9R)]F1 anti-B10.HTT) antisera, when administered in 1 to 10 microliter amounts at the time of immunization, led to twofold increases in the IgM and IgG plaque-forming cells (PFC) responses to suboptimal doses of sheep erythrocytes in A/J (I-Jk) and SJL (I-Js) mice, respectively. To assess whether this immunopotentiation was due to a decrease in specific suppression, experiments were carried out using the polypeptide antigens random linear terpolymer of L-glutamic acid60, L-alanine30, and L-tyrosine10 (GAT) and random linear copolymer of L-glutamic acid50-L-tyrosine50 (GT), since administration of GAT to the nonresponder strain SJL, or GT to the nonresponder strain CBA fails to induce a primary PFC response and stimulates specific suppressor T cells able to prevent PFC responses to subsequent challenge with the immunogens GAT-methylated bovine serum albumin (MBSA) or GT-MBSA, respectively. The current study demonstrates that CBA (I-Jk) mice given 100 microgram GT in Maalox-pertussis adjuvant on day 0, and 10 microliter anti-I-Jk antiserum i.v. on days 0, 1, and 2, develop a significant primary specific PFC response on day 7. A similar responsiveness to 10 microgram GAT is found in SJL mice treated with 10 microliter anti-I-Js antiserum for 3 days. This same active anti-I-Js antiserum does not permit CBA mice to respond to GT, demonstrating the specificity of the anti-I-J effect. These data suggest that anti-I-J antiserum treatment at the time of antigen administration reduces suppressor responses to GAT or GT, permitting primary PFC responses. To directly demonstrate such an effect on suppressor activity, SJL or CBA mice treated, respectively, with GAT or GT to induce suppressor cells active on GAT-MBSA or GT-MBSA responses after adoptive transfer to normal syngeneic recipients were also given anti-I-J antisera (10 microliter/day) for 3 days, at which time their spleen cells were tested for suppressive activity upon transfer. Cells from such treated mice failed to show detectable suppressive activity upon transfer to syngeneic recipients challenged with GAT-MBSA or GT-MBSA, confirming the hypothesis of an in vivo effect of anti-I-J antiserum on suppressor activity.

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 75939      PMCID: PMC2184185          DOI: 10.1084/jem.147.3.656

Source DB:  PubMed          Journal:  J Exp Med        ISSN: 0022-1007            Impact factor:   14.307


  23 in total

1.  Regualtion of the immune response to tumor antigens. I. Immunosuppressor cells in tumor-bearing hosts.

Authors:  S Fujimoto; M I Greene; A H Sehon
Journal:  J Immunol       Date:  1976-03       Impact factor: 5.422

2.  Genetic control of immune responses in vitro. VI. Experimental conditions for the development of helper T-cell activity specific for the terpolymer L-glutamic aicd60-L-alanine30-L-tyrosine10 (GAT) in nonresponder mice.

Authors:  J A Kapp; C W Pierce; B Benacerraf
Journal:  J Exp Med       Date:  1975-07-01       Impact factor: 14.307

3.  Inhibition of immune responses in vitro by specific antiserums to Ia antigens.

Authors:  J A Frelinger; J E Niederhuber; D C Shreffler
Journal:  Science       Date:  1975-04-18       Impact factor: 47.728

4.  A new I subregion (I-J) marked by a locus (Ia-4) controlling surface determinants on suppressor T lymphocytes.

Authors:  D B Murphy; L A Herzenberg; K Okumura; L A Herzenberg; H O McDevitt
Journal:  J Exp Med       Date:  1976-09-01       Impact factor: 14.307

5.  Genetic control of specific immune suppression. I. Experimental conditions for the stimulation of suppressor cells by the copolymer L-glutamic acid50-L-tyrosine50 (GT) in nonresponder BALB/c mice.

Authors:  P Debré; J A Kapp; B Benacerraf
Journal:  J Exp Med       Date:  1975-12-01       Impact factor: 14.307

6.  Properties of the antigen-specific suppressive T-cell factor in the regulation of antibody response of the mouse. IV. Special subregion assignment of the gene(s) that codes for the suppressive T-cell factor in the H-2 histocompatibility complex.

Authors:  T Tada; M Taniguchi; C S David
Journal:  J Exp Med       Date:  1976-09-01       Impact factor: 14.307

7.  T-cell regulation of antibody responses: demonstration of allotype-specific helper T cells and their specific removal by suppressor T cells.

Authors:  L A Herzenberg; K Okumura; H Cantor; V L Sato; F W Shen; E A Boyse; L A Herzenberg
Journal:  J Exp Med       Date:  1976-08-01       Impact factor: 14.307

8.  Genetic control of specific immune suppression. IV. Responsiveness to the random copolymer L-glutamic acid50-L-tyrosine50 induced in BALB/c mice by cyclophosphamide.

Authors:  P Debré; C Waltenbaugh; M E Dorf; B Benacerraf
Journal:  J Exp Med       Date:  1976-07-01       Impact factor: 14.307

9.  Genetic control of specific immune suppression. II. H-2-linked dominant genetic control of immune suppression by the random copolymer L-glutamic acid50-L-tyrosine50 (GT).

Authors:  P Debré; J A Kapp; M E Dorf; B Benacerraf
Journal:  J Exp Med       Date:  1975-12-01       Impact factor: 14.307

10.  Augmentation of delayed-type hypersensitivity by doses of cyclophosphamide which do not affect antibody responses.

Authors:  P W Askenase; B J Hayden; R K Gershon
Journal:  J Exp Med       Date:  1975-03-01       Impact factor: 14.307

View more
  16 in total

1.  Presence of I-region gene products on the cells and their products of the dengue virus-induced suppressor pathway.

Authors:  M I Shukla; U C Chaturvedi
Journal:  Br J Exp Pathol       Date:  1986-08

2.  Suppressor T cells, antigen-presenting cells and the role of I-J restriction in oral tolerance to ovalbumin.

Authors:  A M Mowat; A G Lamont; D M Parrott
Journal:  Immunology       Date:  1988-05       Impact factor: 7.397

3.  Immunosuppressive ALS. II. Antibody to Ia antigens in heterologous anti-lymphocyte serum.

Authors:  B Zimmerman; F Tsui; T Delovitch
Journal:  Immunology       Date:  1979-05       Impact factor: 7.397

4.  H-2-mediated resistance to an ecotropic type C retrovirus: localization of controlling genes and ontogenic studies of resistance.

Authors:  S E Bear; P N Tsichlis; R S Schwartz
Journal:  Immunogenetics       Date:  1980       Impact factor: 2.846

5.  Regulation of antibody heterogeneity by suppressor T cells: diminishing suppressor T cell activity increases the number of dinitrophenyl clones in mice immunized with dinitrophenyl-poly(Glu,Lys,Phe) or dinitrophenyl-poly(Glu,Lys,Ala).

Authors:  T J Kipps; B Benacerraf; M E Dorf
Journal:  Proc Natl Acad Sci U S A       Date:  1978-06       Impact factor: 11.205

Review 6.  Regulation of the immune response to antigens on the malignant cell surface.

Authors:  J A Drebin; L L Perry; R Carter; M I Greene
Journal:  Springer Semin Immunopathol       Date:  1982

7.  Functional clonal deletion in immunological tolerance to major histocompatibility complex antigens.

Authors:  G J Nossal; B L Pike
Journal:  Proc Natl Acad Sci U S A       Date:  1981-06       Impact factor: 11.205

8.  T lymphocyte subpopulations and Ia-positive T cells in patients with immunodeficiency.

Authors:  R C Williams; A D Webster; T Morito; M F Greaves
Journal:  Clin Exp Immunol       Date:  1980-11       Impact factor: 4.330

9.  A role for suppressor T cells in induction of self-tolerance.

Authors:  J Gibson; A Basten; K Z Walker; R H Loblay
Journal:  Proc Natl Acad Sci U S A       Date:  1985-08       Impact factor: 11.205

10.  Murine immune responses to Neisseria meningitidis group C capsular polysaccharide and a thymus-dependent toxoid conjugate vaccine.

Authors:  L J Rubinstein; P A García-Ojeda; F Michon; H J Jennings; K E Stein
Journal:  Infect Immun       Date:  1998-11       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.